Scientific Advisory Board


Oncovita has set-up a Scientific Advisory Board (SAB) to help the company management to refine the company strategy in two domains, i.e. immuno-oncology to treat solid tumors and prophylactic vaccines against infectious diseases.

Yves Fradet - OncovitYves Fradet, MD, PhD

Dr Yves Fradet is professor of surgery at Université Laval (Quebec, Canada) and researcher in cancer immunology and genetics of genitourinary cancers. After completing a research and oncology fellowship at the Memorial Sloan-Kettering Cancer Center, New York, he founded in 1983 a translational and clinical research laboratory whose work has been peer-review funded continuously for more than 37 years. He has established a unique group including six uro-oncologist clinician scientists with high volume patient care, tumor biobanking, pre-clinical models and a very efficient team in investigating new cancer immunotherapy breakthroughs. He has authored more than 340 publications, many in prominent medical and scientific journals, and has been awarded many national and international prizes and recognitions. While clinically and academically active, he was the founder and Chief Medical Officer during 20 years of Diagnocure Inc., a company listed on the Canadian stock market which developed and commercialized new FDA approved cancer diagnostic tests.

Marc GrégoireMarc Grégoire, PhD – Co-Founder

Has dedicated 20 years of his career to cancer research and antitumor treatment development. Together with Frédéric Tangy, he has addressed the potential of cancer virotherapy. Marc Grégoire is Research Director at INSERM in Nantes University Hospital and has recognized expertise in mesothelioma, colorectal cancer and leukemia. During the past decade, he has actively participated in the establishment of vaccine clinical trials with dendritic cells for cancer treatment. He is currently Head of the Center of Research on Oncology and Immunology in Nantes and Angers (CRCINA), Director of the Development and Clinical Transfer Platform and President of the Scientific and Technological Committee at the Clinical Investigation Center in Biotechnology in Nantes. He is also responsible for several committees on cell therapy in cancer treatment and is therefore intensely involved in the development and transfer of effective therapies to clinical trials

Stanley Plotkin, MD

Dr. Stanley A. Plotkin is Emeritus Professor of the University of Pennsylvania. For seven years he was Medical and Scientific Director of Sanofi Pasteur, Paris. He is now consultant to vaccine manufacturers and non-profit research organizations.

He is a member of the Institute of Medicine of the National Academy of Sciences and the French Academy of Medicine. His bibliography includes over 800 articles and he has edited several books including a textbook on vaccines. He developed the rubella vaccine now in standard use throughout the world, is codeveloper of the pentavalent rotavirus vaccine, and has worked extensively on the development and application of other vaccines including anthrax, oral polio, rabies, varicella, and cytomegalovirus.

Jean-François Saluzzo - OncovitaJean-François Saluzzo, Pharm D, Dr.Sc.

He has a long experience in virus vaccines, having been involved in many programs such as yellow fever, haemorrhagic fevers (Ebola, CCHF, RVF). He is a past Director of vaccines production at Sanofi-Pasteur and acts today as an Expert for industry companies and WHO.

Mission and vision


Management team

Board of Directors